Xstrahl in Action Definitive Superficial Radiotherapy for Challenging Skin Cancers – a case series of experiences and learnings.Publication Definitive superficial radiotherapy for challenging skin cancers – a case series of experiences and learningsAuthors Gerald B....
Xstrahl to Highlight Orthovoltage Radiotherapy in Veterinary Oncology at ESVONC 2024. Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will highlight orthovoltage radiation therapy used in veterinary oncology at the ESVONC 2024 conference to be held at The Grand Hotel Bucharest from May 23-25 in Bucharest, Romania.
One of seven of Cancer Research UK’s (CRUK) Centres of Excellence in Radiotherapy Research, the CRUK RadNet Centre Glasgow includes three core laboratory teams of radiation researchers who work within the RadNet initiative to incentivize and encourage other...
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the CalDerm 2024 NorCal Conference at the Meritage Resort & Spa from May 3-5 in Napa, CA.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions at the European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting in Glasgow, UK, May 3-7, 2024, stand # 1070.
For many patients with basal cell carcinomas or squamous cell carcinoma, radiation therapy can yield better functional or cosmetic outcomes than surgical intervention and radiation therapy may be the preferred option. For other patients with medical comorbidities or...
While SARRP is often used to investigate the effect of radiation therapy in preclinical oncology settings, it should be noted that the impact of radiation on normal tissues requires understanding and further research to mitigate both early and late effects. The use of...
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the AOCD 2024 meeting, in Scottsdale, AZ. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring. Visit Xstrahl at AOCD 2024, booth # 22 at the Westin Kierland from April 11-14, 2024.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the Maui Derm Hawaii 2024 meeting, January 22-26, 2024. Radiant Aura is a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
Contact Us